Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Tumor, Radiotherapy, Biomarker. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Predictive Value of Peripheral Blood CHI3L1 for Tumor Radiosensitivity: A Prospective and Retrospective Cohort Study
Overview
Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significantly elevated in patients with radioresistant tumors and may serve as a predictive biomarker for radiotherapy sensitivity. This study aims to conduct a multicenter, bidirectional cohort study to systematically evaluate the predictive value of peripheral blood CHI3L1 as a pan-cancer biomarker for tumor response to radiotherapy.
Primary outcome measures
- Objective Response Rate（ORR） [Time frame: Through study completion, up to 3 years]
Secondary outcome measures (4)
- Local Control Rate [Time frame: Through study completion, up to 3 years]
- Local Relapse Free Survival [Time frame: Through study completion, up to 3 years]
- Progression Free Survival [Time frame: Through study completion, up to 3 years]
- Overall Survival [Time frame: Through study completion, up to 3 years]
Eligibility criteria
Inclusion criteria
- Voluntarily signed informed consent form;
- Age ≥ 18 years;
- No restrictions on sex;
- Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Exclusion criteria
- Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose > 1.5 × ULN), or psychiatric disorders.
- Deemed unsuitable for participation in the study at the discretion of the investigators.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 3 centers
- Nanfang hospital, Southern medical university, Guangzhou, Guangdong 510515 — Guangzhou
- Huizhou Central People's Hospital, Huizhou — Huizhou
- Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou, Meizhou, — Meizhou
Identifiers
NCT: NCT07071688 · NFEC-2025-292